China's Center for Drug Evaluation accepted Merck's application for respiratory syncytial virus or RSV drug Clesrovimab, according to Yicai Global's Thursday report.

The drug was designed to prevent RSV infections in newborns and infants, the report said.

The US Food and Drug Administration's review into the drug is expected to end by June 10. It was first submitted to the FDA in December 2024, the report said.